leisure time -WSS

leisure time

author：explore 2025-10-02 18:46:53 - browse：257

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Wegovy cuts risk of cardiovascular events by 20%, study finds

WSS

Physician subsidies by hospitals soar in wake of No Surprises Act

Medtronic CEO on promising devices for diabetes, hypertension

Emergency medicine has repudiated 'excited delirium.' Now what?

Hospitals use virtual reality to design more inclusive rooms for kids

Meta's Zuckerberg and Chan on track to put $50 billion into science

‘The Bear’ and hospitality in hospitals

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

entertainment

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: XBI biotech index, Akero Therapeutics

Drug repurposing or repositioning? The language matters

WHO may add ‘noma' to its list of neglected tropical diseases

How to save PrEP access — and even expand it

Hospitals use virtual reality to design more inclusive rooms for kids

How to save PrEP access — and even expand it

Biden's order seeks to regulate AI risk without stifling innovation

FDA approval of Sarepta Duchenne genetic therapy gives me hope

CDC recommends rationing of RSV shot due to shortages

focus

Medtronic CEO on promising devices for diabetes, hypertension

Readout Newsletter: What happened with Sarepta's Duchenne data

Telehealth options flood the market as retailers push virtual care

Biden praises World Series champion Astros for impact off the field during White House celebration

FTX founder Sam Bankman

WHO may add ‘noma' to its list of neglected tropical diseases

hotspot

focus

focus

Wikipedia